Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/640540

Variability in Human Drug Metabolizing Cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 Activities Caused by Genetic Variations in Cytochrome P450 Oxidoreductase

Velazques, M. N. R.·Parween, S.·Udhane, S. S.·Pandey, A. V.
View original source ↗Export metadata ↓

Abstract

A broad spectrum of human diseases are caused by mutations in the NADPH cytochrome P450 oxidoreductase (POR). Cytochrome P450 proteins perform several reactions, including the metabolism of steroids, drugs, and other xenobiotics. In 2004 the first human patients with defects in POR were reported, and over 250 variations in POR are known. Information about the effects of POR variants on drug metabolizing enzymes is limited and has not received much attention. By analyzing the POR sequences from genomics databases, we identified potentially disease-causing variations and characterized these by in vitro functional studies using recombinant proteins. Proteins were expressed in bacteria and purified for activity assays. Activities of cytochrome P450 enzymes were tested in vitro using liposomes prepared with lipids into which P450 and P450 reductase proteins were embedded. Here we are reporting the effect of POR variants on drug metabolizing enzymes CYP2C9, CYP2C19, and CYP3A5 which are responsible for the metabolism of many drugs. POR Variants A115V, T142A, A281T, P284L, A287P, and Y607C inhibited activities of all P450 proteins tested. Interestingly, the POR variant Q153R showed a reduction of 20-50% activities with CYP2C9 and CYP2C19 but had a 400% increased activity with CYP3A5. The A287P is most common POR mutation found in patients of European origin, and significantly inhibited drug metabolism activities which has important consequences for monitoring and treatment of patients. In vitro, functional assays using recombinant proteins provide a useful model for establishing the metabolic effect of genetic mutations. Our results indicate that detailed knowledge about POR variants is necessary for correct diagnosis and treatment options for persons with POR deficiency and the role of changes in drug metabolism and toxicology due to variations in POR needs to be addressed.

Source connections

Explore related subjects

pharmacology and toxicologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Velazques, M. N. R., Parween, S., Udhane, S. S., Pandey, A. V.. 2019-05-17. Variability in Human Drug Metabolizing Cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 Activities Caused by Genetic Variations in Cytochrome P450 Oxidoreductase. https://doi.org/10.1101/640540

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗
bioRxiv2026

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗
bioRxiv2019

Levetiracetam inhibits SV2A-synaptotagmin interaction at synapses that lack SV2B

Epilepsy remains a difficult-to-treat neurological disorder prompting the need for new therapies that work via alternate mechanisms. Levetiracetam (LEV) is the first in a series of anti-epilepsy drugs that target presynaptic functioning. LEV binds the synaptic vesicle protein SV2A, and has been shown to decrease neurotransmitter release in hippocampal slices. The molecular basis of LEV action is unknown, however, and direct effects of LEV on SV2A function remain to be determined. SV2A is the most widely expressed paralog of a three-gene family (SV2A, B, C) that is variably co-expressed throughout the CNS. All three SV2s bind the calcium sensor protein synaptotagmin and SV2 plays a crucial role in synaptotagmin stability and trafficking. Here we addressed the action of LEV at the cellular and molecular level asking whether the presence of non-LEV binding SV2 paralogs influences drug action and whether LEV impacts SV2As role in synaptotagmin function. We report that LEV altered short-term synaptic plasticity in isolated neurons from SV2B knockout but not wild-type mice, mimicking the loss of SV2 function. Similarly, LEV reduced SV2A binding to synaptotagmin only in the absence of SV2B. Furthermore, LEV reduced and slowed the internalization of synaptotagmin in neurons cultured from SV2B KO but not WT mice. Taken together, these findings suggest that LEV alters synaptic release probability by disrupting SV2s regulation of synaptotagmin selectively in neurons that express only SV2A. Neurons that meet this requirement include most inhibitory neurons and the granule cells of the dentate gyrus, two classes of neuron implicated in epilepsy.

pharmacology and toxicology↗